Replies to post #17987 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

The Orencia and Necuparanib disclosures didn't attain the threshold of materiality that would mandate a quick 8-K filing, so we can't really grade MNTA's disclosure policy based on those events.

If the above items effect the equity price wouldn't you think they should be reported? Wheeler sold 35K shares in early October, don't you think we should know if he knew Orencia flopped at that point.

[indigokid]

So does the lack of a timely 8K filing regarding the Pfizer Mcpherson plant letter lead one to believe that: a) MNTA 40mg Glatopa is not impacted by the letter indicating delay, b) that MNTA is not viewing this as a material change, or c) something else?